natgillin/translations-raw huggingface dataset:
In general, emtricitabine pharmacokinetics in HBV infected patients was similar to those in healthy subjects and in HIV infected patients. 
Općenito je farmakokinetika emtricitabina u bolesnika zaraženih HBV-om bila slična onoj u zdravih ispitanika i bolesnika inficiranih HIV-om.
Pharmacotherapeutic group: Antiviral for systemic use; antivirals for treatment of HIV infections, combinations. 
Farmakoterapijska skupina: antivirusni lijekovi za sustavnu primjenu, antivirusni lijekovi za liječenje HIV-infekcije, kombinacije.
Your doctor may consider giving you the components of Eviplera separately if you are having problems or need your dose adjusted. 
Liječnik može razmotriti mogućnost da Vam daje sastavne tvari Eviplere zasebno ako imate tegobe ili Vam treba prilagoditi dozu.
In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil as part of a regimen containing a boosted protease inhibitor (PI). 
U drugim ispitivanjima (prospektivnim i presječnim), najizraženija smanjenja BMD-a bila su opažena u bolesnika liječenih tenofovirdizoproksilom u sklopu režima koji je sadržavao pojačan inhibitor proteaze (IP).
As soon as serious skin and/or mucosal reactions are observed, Eviplera must be discontinued and appropriate therapy should be initiated. 
Čim se opaze ozbiljne reakcije kože i/ili sluznica, terapija lijekom Eviplera mora se prekinuti i treba započeti s odgovarajućom terapijom.
Table 1: Interactions between Eviplera or its individual component(s) and other medicinal products 
Tablica 1: Interakcije između lijeka Eviplera ili njegovih pojedinačnih komponenti i drugih lijekova
5 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in hepatitis C virus 
5 Ispitivanje provedeno s dodatnom dozom voksilaprevira od 100 mg kako bi se dosegle izloženosti voksilapreviru očekivane u bolesnika zaraženih virusom hepatitisa C (HCV).
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART. 
Iako se smatra da je etiologija multifaktorska (uključujući primjenu kortikosteroida, konzumaciju alkohola, tešku imunosupresiju, veći indeks tjelesne mase), zabilježeni su slučajevi osteonekroze osobito u bolesnika s uznapredovalom HIV-bolesti i/ili dugotrajnom izloženošću CART-u.
• Dabigatran etexilate, a medicine used to treat heart conditions, as your doctor may need to monitor the levels of this medicine in your blood. 
• Dabigatran eteksilat, lijek koji se primjenjuje za liječenje srčanih bolesti, jer će Vam liječnik možda trebati nadzirati razine tog lijeka u krvi.
The recommended dose of Eviplera is one tablet, taken orally, once daily. 
Preporučena doza lijeka Eviplera je jedna tableta, koja se uzima peroralno jedanput na dan.
 If you think you may have lactic acidosis, tell your doctor immediately. 
 Ako mislite da možda imate laktacidozu, odmah o tome obavijestite liječnika.
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02 to 200 µg/mL. 
In vitro vezanje emtricitabina za proteine ljudske plazme bilo je < 4% i nije ovisilo o koncentraciji u rasponu od 0,02 do 200 µg/ml.
AUC: ↑ Cmax: ↑ Cmin: ↑ 
Tenofovir: AUC: ↑ Cmax: ↑ Cmin: ↑
Your doctor may need to give you an additional dose of rilpivirine to treat your HIV infection (see section 3, How to take Eviplera). 
Vaš liječnik će Vam možda trebati dati dodatnu dozu rilpivirina za liječenje HIV-infekcije (vidjeti dio 3 Kako uzimati Evipleru).
Rilpivirine hydrochloride is primarily metabolised and eliminated by the liver. 
Rilpivirinklorid prvenstveno se metabolizira u jetri i eliminira putem jetre.
Tell your doctor if you are taking any of the following: 
Obavijestite svog liječnika ako uzimate neke od sljedećih lijekova:
A negative impact by NNRTI mutations other than those listed above (e.g. mutations K103N or L100I as single mutations) cannot be excluded, since this was not studied in vivo in a sufficient number of patients. 
Ne može se isključiti negativni učinak NNRTI-mutacija osim onih navedenih gore (npr. mutacije K103N ili L100I kao jedine mutacije), budući da nije ispitan in vivo na dovoljnom broju bolesnika.
The K65R, M184V, and K65R+M184V mutants of HIV-1 remain fully susceptible to rilpivirine. 
Mutacije K65R, M184V i K65R+M184V virusa HIV-1 ostaju potpuno osjetljive na rilpivirin.
No virologic data in week 24 window 
Bez viroloških podataka u okviru 24-tjedna
hypokalaemia3, 5 
hipokalemija3, 5
hypertriglyceridaemia1, 2, hyperglycaemia1, decreased appetite2 
hipertrigliceridemija1, 2, hiperglikemija1 smanjen apetit2
No other pathways of resistance to emtricitabine or tenofovir have been identified. 
Nisu utvrđeni nikakvi drugi putovi rezistencije na emtricitabin ili tenofovir.
Some examples include, but are not limited to, aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2 (also called aldesleukin). 
Neki primjeri uključuju, ali nisu ograničeni na aminoglikozide, amfotericin B, foskarnet, ganciklovir, pentamidin, vankomicin, cidofovir ili interleukin-2 (koji se još zove aldesleukin).
However, it may not be excluded that the pharmacologically active, unbound, rilpivirine exposure is significantly increased in moderate impairment. 
Međutim, ne može se isključiti da je izloženost farmakološki djelatnom, nevezanom rilpivirinu značajno povećana kod umjerenog oštećenja jetre.
The triple combination of emtricitabine, rilpivirine, and tenofovir demonstrated synergistic antiviral activity in cell culture. 
Trojna kombinacija emtricitabina, rilpivirina i tenofovira pokazala je sinergističko antivirusno djelovanje u staničnoj kulturi.
The safety profile of emtricitabine and tenofovir disoproxil in these studies was consistent with the previous experience with these agents when each was administered with other antiretroviral agents. 
Sigurnosni profil emtricitabina i tenofovirdizoproksila u tim je ispitivanjima bio dosljedan prethodnom iskustvu s tim lijekovima kad se svaki primjenjivao s drugim antiretrovirusnim lijekovima.
Please refer to the Summary of Product Characteristics for these medicinal products. 
Molimo pročitajte Sažetak opisa svojstava lijeka tih lijekova.
anaemia1, 4 
anemija1, 4
• Lactic acidosis (excess lactic acid in the blood) is a rare but potentially life-threatening side effect of some HIV medicines. 
• Laktacidoza (suvišak mliječne kiseline u krvi) rijetka je, ali potencijalno životno opasna nuspojava nekih lijekova protiv HIV-a.
Inflammation of the pancreas and lactic acidosis (excess lactic acid in the blood), which sometimes caused death, have been reported rarely when medicines containing tenofovir disoproxil and didanosine were taken together. 
Upala gušterače i laktacidoza (suvišak mliječne kiseline u krvi), koji su ponekad prouzročili smrt, rijetko su zabilježeni kad su se lijekovi koji sadrže tenofovirdizoproksil i didanozin uzimali zajedno.
During the time period of declining efavirenz plasma levels and increasing rilpivirine plasma levels after switching, none of the patients had efavirenz or rilpivirine levels below their respective IC90 levels at the same time. 
Tijekom razdoblja u kojem su razine efavirenza u plazmi opadale, a razine rilpivirina u plazmi povećavale nakon prebacivanja, ni u jednog bolesnika nisu istovremeno razine efavirenza ili rilpivirina bile ispod njihove odgovarajuće IC90.
Emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited. 
Jetreni enzimi ne metaboliziraju emtricitabin u značajnoj mjeri, tako da bi učinak oštećenja jetre trebao biti ograničen.
Following oral administration, the elimination half-life of tenofovir is approximately 12 to 18 hours. 
Nakon peroralne primjene, poluvijek eliminacije tenofovira je približno 12 do 18 sati.
No dose adjustment is required following the switch from an efavirenz-containing regimen. 
Nije potrebna prilagodba doze nakon prebacivanja s režima koji sadrži efavirenz.
Eviplera has not been studied in patients over the age of 65 years. 
Eviplera nije ispitana u bolesnika starijih od 65 godina.
Tenofovir is primarily excreted by the kidney by both filtration and an active tubular transport system (human organic anion transporter 1 [hOAT1]) with approximately 70-80% of the dose excreted unchanged in urine following intravenous administration. 
Tenofovir se prvenstveno izlučuje bubrezima filtracijom i aktivnim tubularnim transportnim sustavom (ljudski transporter organskih aniona 1 [hOAT1]) uz približno 70 - 80% doze izlučene u neizmijenjenom obliku u mokraći nakon intravenske primjene.
Renal clearance has been estimated to be approximately 210 mL/min, which is in excess of the glomerular filtration rate. 
Procijenjeno je da bubrežni klirens iznosi približno 210 ml/min, što je više od brzine glomerularne filtracije.
Emtricitabine triphosphate and tenofovir diphosphate competitively inhibit HIV-1 RT, resulting in DNA chain termination. 
Emtricitabin trifosfat i tenofovirdifosfat kompetitivno inhibiraju HIV-1RT, što rezultira terminacijom DNK lanca.
No clinically relevant drug-drug interaction is expected. 
Ne očekuju se klinički važne interakcije lijekova.
The film-coated tablet should not be chewed, crushed or split as it may impact the absorption of Eviplera. 
Filmom obložena tableta ne smije se žvakati, drobiti ni prelamati jer to može utjecati na apsorpciju lijeka Eviplera.
4 The predominant circulating metabolite of sofosbuvir. 
4 Glavni metabolit sofosbuvira u cirkulaciji.
The K103N substitution alone did not result in reduced susceptibility to rilpivirine, but the combination of K103N and L100I resulted in a 7-fold reduced susceptibility to rilpivirine. 
Samo supstitucija K103N nije rezultirala smanjenom osjetljivošću na rilpivirin, ali kombinacija K103N i L100I rezultirala je sedmerostruko smanjenom osjetljivošću na rilpivirin.
• If you are allergic to emtricitabine, rilpivirine, tenofovir disoproxil, or any of the other ingredients of this medicine (listed in section 6 of this leaflet). 
• Ako ste alergični na emtricitabin, rilpivirin, tenofovirdizoproksil ili neki drugi sastojak ovog lijeka (naveden u dijelu 6 ove upute).
Treatment with Eviplera resulted in an early small increase of mean serum creatinine levels which remained stable over time and is not considered clinically relevant (see section 4.8). 
Liječenje lijekom Eviplera rezultiralo je ranim i malim povećanjem srednje vrijednosti razine kreatinina u serumu koje je ostalo stabilno tijekom vremena i ne smatra se klinički važnim (vidjeti dio 4.8).
After week 24, the HIV-1 from 2 additional patients in the Eviplera arm developed resistance by week 48 (total of 4 of 469 patients, 0.9%). 
Nakon 24. tjedna, virus HIV-1 u 2 dodatna bolesnika u skupini na lijeku Eviplera razvio je rezistenciju do 48. tjedna (ukupno 4 od 469 bolesnika, 0,9%).
• Methadone, a medicine used to treat opiate addiction, as your doctor may need to change your methadone dose. 
• Metadon, lijek koji se primjenjuje za liječenje ovisnosti o opijatima, jer će Vam liječnik možda trebati promijeniti dozu metadona.
As a result, the amounts of Eviplera or other medicines in your blood may be affected. 
Kao rezultat, količine lijeka Eviplera ili drugih lijekova u Vašoj krvi mogu biti promijenjene.
• Medicines for stomach ulcers, heartburn or acid reflux such as: 
• Lijekovi za liječenje ulkusa želuca, žgaravice i bolesti refluksa kiseline kao što su:
If you have hepatitis B infection, liver problems may become worse after you stop taking Eviplera. 
Ako imate infekciju hepatitisom B, ove se tegobe s jetrom mogu pogoršati nakon što prestanete uzimati lijek Eviplera.
pancreatitis3 
pankreatitis3
However, there was no increased risk of fractures or evidence for clinically relevant bone abnormalities over 144 weeks. 
Međutim, tijekom ta 144 tjedna nije bilo povećanog rizika od prijeloma ni dokaza klinički važnih abnormalnosti kostiju.
Any signs of inflammation or infection. 
Bilo koji znak upale ili infekcije.
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice. 
Bolesnici s otprije postojećim poremećajem funkcije jetre, uključujući kronični aktivni hepatitis, imaju povećani broj abnormalnosti funkcije jetre tijekom kombinirane antiretrovirusne terapije (CART, combination antiretroviral therapy) pa ih treba nadzirati u skladu sa standardnom praksom.
Lower exposures of rilpivirine were observed when rilpivirine 25 mg once daily was taken during pregnancy. 
Manje izloženosti rilpivirinu opažene su kada je rilpivirin 25 mg uziman jedanput na dan tijekom trudnoće.
• Anaemia (low red blood cell count) 
• anemija (nizak broj crvenih krvnih stanica)
The resistance outcome for patients with protocol defined virological failure and phenotypic resistance at week 96 are shown in Table 6: 
Ishodi rezistencije u bolesnika s protokolom definiranim virološkim neuspjehom i fenotipskom rezistencijom u 96. tjednu prikazani su u tablici 6:
There is insufficient information on the effects of Eviplera in newborns/infants. 
Nema dovoljno podataka o učincima lijeka Eviplera na novorođenčad/dojenčad.
Only trace amounts of unchanged rilpivirine (< 1% of dose) were detected in urine. 
U mokraći su otkrivene samo količine rilpivirina u tragovima (< 1% doze).
If you do miss a dose: 
Ako propustite dozu:
Study GS-US-264-0106 
Ispitivanje GS-US-264-0106
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. 
U nekih bolesnika s uznapredovalom HIV-bolešću (SIDA) i oportunističkim infekcijama u povijesti bolesti (infekcije koje nastaju u osoba sa slabim imunološkim sustavom) mogu se pojaviti znakovi i simptomi upale prethodnih infekcija ubrzo nakon početka liječenja protiv HIV-a.
If you accidentally take more than the recommended dose of Eviplera you may be at increased risk of experiencing possible side effects with this medicine (see section 4, Possible side effects). 
Ako slučajno uzmete više od preporučene doze Eviplere, može Vam se povećati rizik od mogućih nuspojava ovog lijeka (pogledajte dio 4 Moguće nuspojave).
• Tell your doctor if you have an allergy to sunset yellow aluminium lake (E110). 
• Obavijestite svog liječnika ako ste alergični na boju sunset yellow aluminium lake (E110).
Liver toxicity associated with liver enzyme induction was observed in rodents. 
Jetrena toksičnost povezana s indukcijom jetrenih enzima primijećena je u glodavaca.
• dexamethasone (a corticosteroid used to treat inflammation and suppress the immune system) when taken by mouth or injected (except as a single dose treatment) 
• deksametazon (primjena kortikosteroida za liječenje upale i potiskivanja imunološkog sustava) kad se uzima na usta ili daje injekcijom (osim kao liječenje jednom dozom)
• Pain, stomach pain or discomfort, feeling bloated, dry mouth 
• bol, bolovi ili nelagoda u trbuhu, osjećaj nadutosti, suha usta
Eviplera must be taken orally, once daily with food (see section 5.2). 
Eviplera se mora uzimati peroralno, jedanput na dan s hranom (vidjeti dio 5.2).
Not enough patients over the age of 65 
Nije ispitan dovoljan broj bolesnika u dobi iznad 65 godina.
If Eviplera is stopped your doctor may recommend that you resume hepatitis B treatment. 
Ako se prekine liječenje Eviplerom, liječnik može preporučiti da nastavite liječenje hepatitisa B.
• If you notice after 12 hours or more of the time you usually take Eviplera, then do not take the missed dose. 
• Ako to primijetite a prošlo je 12 sati ili više od vremena kada obično uzimate Evipleru, tada propuštenu dozu nemojte uzeti.
A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor foetal/neonatal toxicity associated with emtricitabine and tenofovir disoproxil. 
Opsežni podaci (više od 1000 trudnoća) ne ukazuju na postojanje malformacija i feto/neonatalno toksičnog učinka povezanog s emtricitabinom i tenofovirdizoproksilom.
A subgroup of patients with baseline CrCl between 50 and 60 mL/min, receiving once daily dosing, had a 2- to 4-fold increase in tenofovir exposure and worsening renal function. 
Podskupina bolesnika s početnim CrCl između 50 i 60 ml/min, koji su primali dozu jedanput na dan, imala je od 2 do 4 puta povećanu izloženost tenofoviru i pogoršanje funkcije bubrega.
• If you are taking an antacid (such as medicines containing magnesium or potassium), take it at least 2 hours before or at least 4 hours after Eviplera (see section 3, How to take Eviplera). 
• Ako uzimate antacid (primjerice lijekove koje sadrže magnezij ili kalij), uzmite ga najmanje 2 sata prije ili najmanje 4 sata poslije lijeka Eviplera (vidjeti dio 3 Kako uzimati Evipleru).
In faeces, unchanged rilpivirine accounted for on average 25% of the administered dose. 
U stolici je neizmijenjeni rilpivirin predstavljao u prosjeku 25% primijenjene doze.
At week 48, 94% (46/49) of patients remained suppressed, and 4% (2/49) were considered virologic failures (HIV-1 RNA ≥ 50 copies/mL). 
U 48. tjednu, 94% (46/49) bolesnika ostalo je suprimirano, a 4% (2/49) smatrano je virološkim neuspjehom (HIV-1 RNK ≥ 50 kopija/ml).
Following oral administration of Eviplera with food emtricitabine is rapidly and extensively absorbed with maximum plasma concentrations occurring within 2.5 hours post-dose. 
Nakon peroralne primjene lijeka Eviplera uz hranu emtricitabin se brzo i opsežno apsorbira i postiže maksimalnu koncentraciju u plazmi u roku od 2,5 sata nakon doziranja.
In vitro studies have determined that neither tenofovir disoproxil nor tenofovir are substrates for the CYP450 enzymes. 
In vitro ispitivanjima utvrdilo se da ni tenofovirdizoproksil ni tenofovir nisu supstrati enzima CYP450.
Bone toxicity was diagnosed as osteomalacia (monkeys) and reduced BMD (rats and dogs). 
Toksičnost za kosti dijagnosticirala se kao osteomalacija (majmuni) i smanjena mineralna gustoća kostiju (štakori i psi).
If you forget to take Eviplera 
Ako ste zaboravili uzeti Evipleru
• Decrease in haemoglobin in your blood (low red blood cell count) 
• smanjenje hemoglobina u vašoj krvi (nizak broj crvenih krvnih stanica)
• proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole, 
• inhibitori protonske pumpe, kao što su omeprazol, esomeprazol, lansoprazol, pantoprazol,
proximal renal tubulopathy including Fanconi syndrome3, increased creatinine3, proteinuria3 
proksimalna bubrežna tubulopatija uključujući Fanconijev sindrom3, povišen kreatinin3, proteinurija3
Some patients taking combination antiretroviral medicines such as Eviplera may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). 
Neki bolesnici koji uzimaju kombinirane antiretrovirusne lijekove kao što je Eviplera mogu razviti bolest kostiju koja se zove osteonekroza (odumiranje koštanog tkiva prouzročeno gubitkom prokrvljenosti kosti).
There is no specific antidote for overdose with Eviplera. 
Ne postoji specifični antidot za predoziranje lijekom Eviplera.
• aminoglycosides (such as streptomycin, neomycin and gentamicin), vancomycin (for bacterial infections) 
• aminoglikozide (kao što su streptomicin, neomicin i gentamicin), vankomicin (za bakterijske infekcije)
The following may be signs of lactic acidosis: 
Sljedeći znakovi mogu ukazivati na laktacidozu:
Findings in repeated dose toxicity studies in rats, dogs and monkeys at exposure levels greater than or equal to clinical exposure levels and with possible relevance to clinical use included kidney and bone changes and a decrease in serum phosphate concentration. 
Nalazi ispitivanja toksičnosti ponovljenih doza u štakora, pasa i majmuna pri razini izloženosti većoj ili jednakoj razinama kliničke izloženosti i s mogućom važnošću za kliničku primjenu, uključivali su promjene na bubrezima i kostima i smanjenje koncentracije fosfata u serumu.
In a clinical study rilpivirine did not significantly affect the pharmacokinetics of digoxin. 
U kliničkom ispitivanju rilpivirin nije značajno utjecao na farmakokinetiku digoksina.
Tenofovir disoproxil should be avoided in patients with HIV-1 harbouring the K65R mutation. 
Tenofovirdizoproksil treba izbjegavati u bolesnika s HIV-1 koji nose mutaciju K65R.
Rilpivirine is an in vitro inhibitor of the transporter MATE-2K with an IC50 of < 2.7 nM. 
Rilpivirin je in vitro inhibitor transportera MATE-2K, s IC50 od < 2,7 nM.
The pharmacokinetics of rilpivirine and tenofovir disoproxil in children and adolescents are under investigation. 
Farmakokinetika rilpivirina i tenofovirdizoproksila u djece i adolescenata još se ispituje.
In vitro experiments indicate that rilpivirine hydrochloride primarily undergoes oxidative metabolism mediated by the CYP3A system. 
In vitro pokusi pokazuju da rilpivirinklorid prvenstveno prolazi oksidativni metabolizam posredovan sustavom CYP3A.
When your supply of Eviplera starts to run low, get more from your doctor or pharmacist. 
Kad Vam se smanji zaliha Eviplere, nabavite još lijeka od liječnika ili ljekarnika.
Ethnicity No clinically important pharmacokinetic differences due to ethnicity have been identified. 
Etnička pripadnost Nisu utvrđene klinički važne farmakokinetičke razlike zbog etničke pripadnosti.
Emtricitabine and tenofovir pharmacokinetics are similar in male and female patients. 
Farmakokinetika emtricitabina i tenofovira slične su u bolesnika muškog i ženskog spola.
Discontinued study drug due to other reasons and last available HIV-1 RNA < 50 copies/mLe 
Prekid primjene ispitivanog lijeka iz drugih razloga, a posljednje dostupne vrijednosti HIV-1 RNK < 50 kopija/mle
Each film-coated tablet contains 277 mg lactose monohydrate and 4 micrograms sunset yellow aluminium lake (E110). 
Jedna filmom obložena tableta sadrži 277 mg laktoza hidrata i 4 mikrograma boje sunset yellow aluminium lake (E110).
(≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) or rare (≥ 1/10,000 to < 1/1,000). 
Učestalost se definira kao vrlo često (≥ 1/10), često (≥ 1/100 i< 1/10), manje često (≥ 1/1000 i< 1/100) ili rijetko (≥ 1/10 000 i< 1/1000).
In the Phase III studies (C209 and C215), lower rilpivirine exposure, similar to that seen during pregnancy, has been associated with an increased risk of virological failure, therefore viral load should be monitored closely (see sections 4.6, 5.1 and 5.2). 
U ispitivanjima III. faze (C209 i C215), manja izloženost rilpivirinu slična onoj opaženoj tijekom trudnoće, povezana je s povećanim rizikom od virološkog neuspjeha pa je stoga potrebno pažljivo pratiti virusno opterećenje (vidjeti dijelove 4.6, 5.1 i 5.2).
Patients co-infected with HIV and HBV who discontinue Eviplera should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. 
Bolesnike istovremeno zaražene HIV-om i HBV-om koji prekinu terapiju lijekom Eviplera treba pažljivo klinički i laboratorijski pratiti najmanje nekoliko mjeseci nakon prestanka liječenja.
• Joint aches and pains (especially of the hip, knee and shoulder) 
• bolovi u zglobovima (osobito u kuku, koljenu i ramenu)
d Includes patients who discontinued due to AE or death at any time point from day 1 through the week 24 window resulting in no virologic data on treatment during the specified window. 
d Obuhvaća bolesnike koji su prekinuli zbog nuspojave ili smrti u bilo kojem trenutku od 1. dana do 24. tjedna što je rezultiralo nedostatkom viroloških podataka o liječenju tijekom navedenog vremenskog okvira.
Neither emtricitabine nor tenofovir inhibited in vitro drug metabolism mediated by any of the major human CYP450 isoforms involved in drug biotransformation. 
Niti emtricitabin niti tenofovir nisu inhibirali in vitro metabolizam lijekova posredovan nekim od glavnih izooblika ljudskog CYP450 uključenih u biotransformaciju lijekova.